- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06233994
A Study Evaluating the Efficacy and Safety of ZG005 in Combination With Donafenib or Bevacizumab in Patients With Advanced Hepatocellular Carcinoma
January 23, 2024 updated by: Changsha Taihe Hospital
A Study Evaluating the Efficacy and Safety of ZG005 in Combination With Donafenib Tosilate Tablets or Bevacizumab as First-line Treatment in Patients With Advanced Hepatocellular Carcinoma
This is a randomized, open-label study to evaluate the safety and efficacy of ZG005 in combination with Donafenib or Bevacizumab in patients with advanced hepatocellular carcinoma.
Study Overview
Status
Not yet recruiting
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Estimated)
30
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Yongsheng Chu
- Phone Number: +8651257309965
- Email: chuys@zelgen.com
Study Locations
-
-
Hunan
-
Changsha, Hunan, China
- Changsha Taihe Hospital
-
Contact:
- Xiaoli Chai
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Male or female ≥18 years of age.
- Fully understand the study and voluntarily sign the informed consent form.
- Histologically or cytologically confirmed diagnosis of metastatic or unresectable hepatocellular carcinoma (HCC).
- Life expectancy >= 3 months.
- Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1.
Exclusion Criteria:
- Fibrolamellar or sarcomatoid HCC, or mixed cholangiocarcinoma and HCC.
- Patients were deemed unsuitable for participating in the studyl by the investigator for any reasons.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: ZG005+Donafenib
Participants will receive ZG005 plus Donafenib until unacceptable toxicity or loss of clinical benefit.
|
ZG005 will be administered at a dose of 10 mg/kg by intravenous (IV) infusion, once every 3 weeks (Q3W).
Other Names:
Donafenib will be administered at a dose of 0.2 g by orally, Bis in die(Bid).
Other Names:
|
Experimental: ZG005+Bevacizumab
Participants will receive ZG005 plus bevacizumab until unacceptable toxicity or loss of clinical benefit.
|
ZG005 will be administered at a dose of 10 mg/kg by intravenous (IV) infusion, once every 3 weeks (Q3W).
Other Names:
Bevacizumab will be administered at a dose of 15 mg/kg by IV infusion, once every 3 weeks (Q3W).
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Objective Response Rate (ORR)
Time Frame: up to approximately 2 years
|
The sum of the proportions of subjects who achieved CR or PR in imaging evaluation as assessed by the investigator based on RECIST1.1 criteria.
|
up to approximately 2 years
|
Progression Free Survival (PFS)
Time Frame: up to approximately 2 years
|
Time from first dose of the investigational drug to PD or death from any cause.
|
up to approximately 2 years
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Xiaoli Chai, Changsha Taihe Hospital
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Estimated)
January 1, 2024
Primary Completion (Estimated)
January 1, 2026
Study Completion (Estimated)
January 1, 2026
Study Registration Dates
First Submitted
January 23, 2024
First Submitted That Met QC Criteria
January 23, 2024
First Posted (Actual)
January 31, 2024
Study Record Updates
Last Update Posted (Actual)
January 31, 2024
Last Update Submitted That Met QC Criteria
January 23, 2024
Last Verified
January 1, 2024
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Digestive System Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Neoplasms by Site
- Adenocarcinoma
- Neoplasms, Glandular and Epithelial
- Digestive System Neoplasms
- Liver Diseases
- Liver Neoplasms
- Carcinoma
- Carcinoma, Hepatocellular
- Physiological Effects of Drugs
- Antineoplastic Agents
- Antineoplastic Agents, Immunological
- Angiogenesis Inhibitors
- Angiogenesis Modulating Agents
- Growth Substances
- Growth Inhibitors
- Bevacizumab
Other Study ID Numbers
- ZG005-IIT-001
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Advanced Hepatocellular Carcinoma
-
City of Hope Medical CenterNational Cancer Institute (NCI)CompletedAdvanced Adult Hepatocellular Carcinoma | Advanced Adult Primary Liver Cancer | Adult Primary Hepatocellular Carcinoma | BCLC Stage B Adult Hepatocellular Carcinoma | BCLC Stage C Adult Hepatocellular CarcinomaUnited States
-
Jonsson Comprehensive Cancer CenterMerck Sharp & Dohme LLC; Highlight TherapeuticsTerminatedAdvanced Hepatocellular Carcinoma | BCLC Stage B Hepatocellular Carcinoma | BCLC Stage C Hepatocellular Carcinoma | Refractory Hepatocellular CarcinomaUnited States
-
Roswell Park Cancer InstituteMerck Sharp & Dohme LLCActive, not recruitingAdvanced Adult Hepatocellular Carcinoma | Child-Pugh Class A | Stage III Hepatocellular Carcinoma | Stage IIIA Hepatocellular Carcinoma | Stage IIIB Hepatocellular Carcinoma | Stage IIIC Hepatocellular Carcinoma | Stage IV Hepatocellular Carcinoma | Stage IVA Hepatocellular Carcinoma | Stage IVB Hepatocellular...United States
-
Mayo ClinicNational Cancer Institute (NCI)RecruitingAdvanced Hepatocellular Carcinoma | BCLC Stage B Hepatocellular Carcinoma | BCLC Stage C Hepatocellular Carcinoma | Metastatic Hepatocellular Carcinoma | BCLC Stage A Hepatocellular CarcinomaUnited States
-
The University of Hong KongUnknownAdvanced Hepatocellular Carcinoma | Metastatic Hepatocellular CarcinomaChina
-
Roswell Park Cancer InstituteNational Comprehensive Cancer NetworkCompletedAdvanced Adult Hepatocellular Carcinoma | Localized Non-Resectable Adult Hepatocellular Carcinoma | Stage IIIA Hepatocellular Carcinoma | Stage IIIB Hepatocellular Carcinoma | Stage IIIC Hepatocellular Carcinoma | Stage IVA Hepatocellular Carcinoma | Stage IVB Hepatocellular Carcinoma | Stage III... and other conditionsUnited States
-
Mayo ClinicRecruitingAdvanced Hepatocellular Carcinoma | Unresectable Hepatocellular Carcinoma | Stage III Hepatocellular Carcinoma AJCC v8 | Stage IV Hepatocellular Carcinoma AJCC v8United States
-
University of WashingtonExelixisTerminatedAdvanced Hepatocellular Carcinoma | BCLC Stage B Hepatocellular Carcinoma | BCLC Stage C Hepatocellular CarcinomaUnited States
-
AmgenCompletedAdvanced Hepatocellular Carcinoma | Inoperable Hepatocellular Carcinoma
-
AstraZenecaIonis Pharmaceuticals, Inc.CompletedAdvanced Adult Hepatocellular Carcinoma | Hepatocellular Carcinoma MetastaticKorea, Republic of, Taiwan, Hong Kong, Japan
Clinical Trials on ZG005 Powder for Injection
-
Suzhou Zelgen Biopharmaceuticals Co.,LtdRecruiting
-
Suzhou Zelgen Biopharmaceuticals Co.,LtdNot yet recruiting
-
SirnaomicsActive, not recruiting
-
SirnaomicsCompletedFacial isSCCUnited States
-
SirnaomicsAmarex Clinical ResearchCompletedBasal Cell CarcinomaUnited States
-
SirnaomicsCompletedAbdominal ObesityUnited States
-
Suzhou Zelgen Biopharmaceuticals Co.,LtdRecruiting
-
SirnaomicsCompleted
-
SirnaomicsCompletedSquamous Cell Carcinoma in SituUnited States
-
SirnaomicsTranslational Drug DevelopmentCompletedHepatocellular Carcinoma | Cholangiocarcinoma | Liver MetastasesUnited States